We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Epix Pharmaceuticals has received an approvable letter from the FDA for MS-325,
a blood pool management agent for magnetic resonance angiography (MRA).
Rigel Pharmaceuticals and Pfizer have entered into a collaborative research
and license agreement for the development of inhaled products for the treatment
of allergic asthma and other respiratory diseases, such as chronic obstructive
pulmonary disease.
GenVec has signed a $1.6 million contract with the Defense Department to manufacture
an adenovector based malaria vaccine candidate for the U.S. Naval Medical
Research Center (NMRC) using GenVec's proprietary adenovector technology and
293-ORF6 cell-line based manufacturing process.
GenVec has announced that the National Institute of Allergy and Infectious Diseases
(NIAID), part of NIH, has begun the second Phase I clinical trial in healthy
adult volunteers of an HIV vaccine candidate.
Allos Therapeutics has initiated a Phase I dose-escalation study of its investigational
drug PDX (pralatrexate) with vitamin B12 and folic acid supplementation in patients
with previously-treated (Stage IIIB-IV) advanced non-small cell lung cancer
(NSCLC).
OSI Pharmaceuticals has announced that Prosidion, its UK subsidiary focused
on the discovery and development of diabetes and obesity therapeutics, has initiated
a Phase II proof-of-concept and dose-range finding study with the Dipeptidyl
Peptidase-IV (DP-IV) inhibitor PSN9301.
Progenics Pharmaceuticals has announced positive top-line results from a Phase
II clinical trial of its investigational drug, methylnaltrexone (MNTX) for the
management of postoperative bowel dysfunction.